title: Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis.
abstract: Cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS). Interleukin (IL)-33, one of the recently discovered members of the IL-1 superfamily, is a dual functional cytokine involved in various autoimmune disorders. In a case-control study, venous blood was collected from healthy subjects categorized as control group (n=44) and MS patients (n=44). All recruited patients were clinically diagnosed with relapsing-remitting MS (RRMS), including patients without treatment (new identified cases, n=16) and those treated with interferon beta (IFN-β) (n=28). The plasma levels of IL-33 in subjects were measured with ELISA. Significantly elevated IL-33 plasma levels were observed in RRMS patients (p=0.005). Furthermore, IFN-β-treated MS patients had lower levels of IL-33 compared to the untreated patients (p<0.001). Increased IL-33 plasma levels in the patient group might be associated with development of MS. These results could contribute to our better understanding about the role of IL-33 in the immunopathogenesis of MS.
authors.affiliation: Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Fereshteh
authors.initials: F
authors.lastname: Alsahebfosoul
authors.affiliation: Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|Departments of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Ilnaz
authors.initials: I
authors.lastname: Rahimmanesh
authors.affiliation: Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Mansour
authors.initials: M
authors.lastname: Shajarian
authors.affiliation: Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Masoud
authors.initials: M
authors.lastname: Etemadifar
authors.affiliation: Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Nahid
authors.initials: N
authors.lastname: Sedaghat
authors.affiliation: Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|Departments of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Hejazi
authors.affiliation: Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.|Departments of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Shamsi
authors.initials: S
authors.lastname: Naderi
mesh_terms: D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use; D000067596:Interleukin-33 / Q000097:blood*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000188:drug therapy
chemical_list: C506536:IL33 protein, human; D000067596:Interleukin-33; D016899:Interferon-beta